At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Biopsy, Biospecimen Collection, and 4 other interventions for Anatomic Stage III Breast Cancer AJCC v8 and 4 related conditions. Completed, enrolled 77 participants across 23 sites in 2 countries.
Detailed Summary
This phase II trial studies how well veliparib with or without carboplatin works in treating patients with stage III or IV breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether veliparib is more effective with or without carboplatin in treating breast cancer.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo blood sample collection
Given IV
Undergo CT
Undergo MRI
Given PO